Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 6/20 | 0.43 |
| ▸ | IDO1 | P14902 | 2/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | PRSS1 | P07477 | 5/20 | 0.36 |
| ▸ | HTR1A | P08908 | 1/20 | 0.35 |
| ▸ | HTR7 | P34969 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22345190 | 0.82 | APP (0.43) | APPIDO1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL21246500 | 0.80 | APP (0.42) | APPIDO1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL5743833 | 0.80 | TP53 (0.59) | APPTP53CYP3A4ALDH1A1TSHR | |
| SCHEMBL3158232 | 0.80 | APP (0.42) | APPIDO1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL16175865 | 0.77 | TP53 (0.39) | APPTP53CYP3A4ALDH1A1TSHR | |
| SCHEMBL10458635 | 0.77 | KCNH2 (0.44) | APPPRSS1HTR1AHTR7 | |
| SCHEMBL6481122 | 0.77 | IDO1 (0.41) | APPIDO1PRSS1HTR1AHTR7 | |
| SCHEMBL22296966 | 0.77 | KCNA3 (0.64) | PRSS1ALDH1A1 | |
| SCHEMBL17858493 | 0.77 | NPC1 (0.43) | APPPRSS1HTR1AHTR7SMN1; SMN2 | |
| SCHEMBL3657469 | 0.77 | APP (0.46) | APPIDO1SLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3741392-A1 | POSITRON EMISSION TOMOGRAPHY RADIOTRACER FOR DISEASES ASSOCIATED WITH TRANSLOCATOR PROTEIN OVEREXPRESSION, TRANSLOCATOR PROTEIN-TARGETING LIGAND FOR FLUORESCENCE IMAGING DIAGNOSIS AND PHOTODYNAMIC THERAPY, AND PREPARATION METHOD THEREFOR | Seoul National University R & DB Foundation (KR) | 2020-11-25 | — | — | EP | claimed |
| CN-111954543-A | Positron emission tomography radioactive tracer for translocator overexpression related diseases, translocator targeting ligand for fluorescence imaging diagnosis and photodynamic therapy and preparation method thereof | 首尔国立大学校产学协力财团 | 2020-11-17 | — | — | CN | claimed |
| US-20200345870-A1 | POSITRON EMISSION TOMOGRAPHY RADIOTRACER FOR DISEASES ASSOCIATED WITH TRANSLOCATOR PROTEIN OVEREXPRESSION, TRANSLOCATOR PROTEIN-TARGETING LIGAND FOR FLUORESCENCE IMAGING-GUIDED SURGERY AND PHOTODYNAMIC THERAPY, AND PRODUCTION METHODS THEREFOR | SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION (KR) | 2020-11-05 | — | — | US | claimed |
| WO-2019143016-A9 | POSITRON EMISSION TOMOGRAPHY RADIOTRACER FOR DISEASES ASSOCIATED WITH TRANSLOCATOR PROTEIN OVEREXPRESSION, TRANSLOCATOR PROTEIN-TARGETING LIGAND FOR FLUORESCENCE IMAGING DIAGNOSIS AND PHOTODYNAMIC THERAPY, AND PREPARATION METHOD THEREFOR | 서울대학교산학협력단 | 2020-08-20 | — | — | WO | claimed |
| WO-2019143016-A1 | POSITRON EMISSION TOMOGRAPHY RADIOTRACER FOR DISEASES ASSOCIATED WITH TRANSLOCATOR PROTEIN OVEREXPRESSION, TRANSLOCATOR PROTEIN-TARGETING LIGAND FOR FLUORESCENCE IMAGING DIAGNOSIS AND PHOTODYNAMIC THERAPY, AND PREPARATION METHOD THEREFOR | 서울대학교산학협력단 | 2019-07-25 | — | — | WO | claimed |
| US-20260061083-A1 | POSITRON EMISSION TOMOGRAPHY RADIOTRACER FOR DISEASES ASSOCIATED WITH TRANSLOCATOR PROTEIN OVEREXPRESSION, TRANSLOCATOR PROTEIN-TARGETING LIGAND FOR FLUORESCENCE IMAGING-GUIDED SURGERY AND PHOTODYNAMIC THERAPY, AND PRODUCTION METHODS THEREFOR | SEOUL NATIONAL UNIVERSITY R&DB FOUNDATGON (KR) | 2026-03-05 | — | — | US | disclosed |
| US-12491271-B2 | Positron emission tomography radiotracer for diseases associated with translocator protein overexpression, translocator protein-targeting ligand for fluorescence imaging-guided surgery and photodynamic therapy, and production methods therefor | SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION (KR) | 2025-12-09 | — | — | US | disclosed |
| US-20240156997-A1 | POSITRON EMISSION TOMOGRAPHY RADIOTRACER FOR DISEASES ASSOCIATED WITH TRANSLOCATOR PROTEIN OVEREXPRESSION, TRANSLOCATOR PROTEIN-TARGETING LIGAND FOR FLUORESCENCE IMAGING-GUIDED SURGERY AND PHOTODYNAMIC THERAPY, AND PRODUCTION METHODS THEREFOR | SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION (KR) | 2024-05-16 | — | — | US | disclosed |
| EP-3741392-A1 | POSITRON EMISSION TOMOGRAPHY RADIOTRACER FOR DISEASES ASSOCIATED WITH TRANSLOCATOR PROTEIN OVEREXPRESSION, TRANSLOCATOR PROTEIN-TARGETING LIGAND FOR FLUORESCENCE IMAGING DIAGNOSIS AND PHOTODYNAMIC THERAPY, AND PREPARATION METHOD THEREFOR | Seoul National University R & DB Foundation (KR) | 2020-11-25 | — | — | EP | disclosed |
| CN-111954543-A | Positron emission tomography radioactive tracer for translocator overexpression related diseases, translocator targeting ligand for fluorescence imaging diagnosis and photodynamic therapy and preparation method thereof | 首尔国立大学校产学协力财团 | 2020-11-17 | — | — | CN | disclosed |
| US-20200345870-A1 | POSITRON EMISSION TOMOGRAPHY RADIOTRACER FOR DISEASES ASSOCIATED WITH TRANSLOCATOR PROTEIN OVEREXPRESSION, TRANSLOCATOR PROTEIN-TARGETING LIGAND FOR FLUORESCENCE IMAGING-GUIDED SURGERY AND PHOTODYNAMIC THERAPY, AND PRODUCTION METHODS THEREFOR | SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION (KR) | 2020-11-05 | — | — | US | disclosed |
| WO-2019143016-A9 | POSITRON EMISSION TOMOGRAPHY RADIOTRACER FOR DISEASES ASSOCIATED WITH TRANSLOCATOR PROTEIN OVEREXPRESSION, TRANSLOCATOR PROTEIN-TARGETING LIGAND FOR FLUORESCENCE IMAGING DIAGNOSIS AND PHOTODYNAMIC THERAPY, AND PREPARATION METHOD THEREFOR | 서울대학교산학협력단 | 2020-08-20 | — | — | WO | disclosed |
| WO-2019143016-A1 | POSITRON EMISSION TOMOGRAPHY RADIOTRACER FOR DISEASES ASSOCIATED WITH TRANSLOCATOR PROTEIN OVEREXPRESSION, TRANSLOCATOR PROTEIN-TARGETING LIGAND FOR FLUORESCENCE IMAGING DIAGNOSIS AND PHOTODYNAMIC THERAPY, AND PREPARATION METHOD THEREFOR | 서울대학교산학협력단 | 2019-07-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260061083-A1 | POSITRON EMISSION TOMOGRAPHY RADIOTRACER FOR DISEASES ASSOCIATED WITH TRANSLOCATOR PROTEIN OVEREXPRESSION, TRANSLOCATOR PROTEIN-TARGETING LIGAND FOR FLUORESCENCE IMAGING-GUIDED SURGERY AND PHOTODYNAMIC THERAPY, AND PRODUCTION METHODS THEREFOR | TSPO, FABP7, SLC46A1 | APP 351/4885IDO1 3528/4885SLC6A2 159/4885 |
| US-12491271-B2 | Positron emission tomography radiotracer for diseases associated with translocator protein overexpression, translocator protein-targeting ligand for fluorescence imaging-guided surgery and photodynamic therapy, and production methods therefor | TSPO, FABP7, SLC46A1 | APP 95/4885IDO1 3707/4885SLC6A2 333/4885 |
| US-20240156997-A1 | POSITRON EMISSION TOMOGRAPHY RADIOTRACER FOR DISEASES ASSOCIATED WITH TRANSLOCATOR PROTEIN OVEREXPRESSION, TRANSLOCATOR PROTEIN-TARGETING LIGAND FOR FLUORESCENCE IMAGING-GUIDED SURGERY AND PHOTODYNAMIC THERAPY, AND PRODUCTION METHODS THEREFOR | TSPO, FABP7, SLC46A1 | APP 95/4885IDO1 3707/4885SLC6A2 333/4885 |
| US-20200345870-A1 | POSITRON EMISSION TOMOGRAPHY RADIOTRACER FOR DISEASES ASSOCIATED WITH TRANSLOCATOR PROTEIN OVEREXPRESSION, TRANSLOCATOR PROTEIN-TARGETING LIGAND FOR FLUORESCENCE IMAGING-GUIDED SURGERY AND PHOTODYNAMIC THERAPY, AND PRODUCTION METHODS THEREFOR | TSPO, TMEM14C, FABP7 | APP 1169/4885IDO1 2598/4885SLC6A2 172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.